English | 简体中文 | LP ACCESS

About artrix

This author has not yet filled in any details.
So far artrix has created 73 blog entries.

RareStone’s pitolisant (Wakix) was approved by China NMPA for the treatment of narcolepsy, and became the first approved innovative drug for narcolepsy and the only non-scheduled drug with narcolepsy indication

RareStone’s pitolisant (Wakix) was approved by China NMPA for the treatment of narcolepsy, and became the first approved innovative drug for narcolepsy and the only non-scheduled drug with narcolepsy indication2023-07-06T23:39:04-07:00

ScienTech Medical Technology, a Vivo Capital portfolio company, Successfully Lists on the Main Board of Hong Kong Stock Exchange

ScienTech Medical Technology, a Vivo Capital portfolio company, Successfully Lists on the Main Board of Hong Kong Stock Exchange2022-11-09T23:02:31-08:00

Vivo Capital Invests in Zenas Biopharma’s $118 Million Financing to Advance the Company’s Broad Pipeline of Autoimmune Disease Therapeutics

Vivo Capital Invests in Zenas Biopharma’s $118 Million Financing to Advance the Company’s Broad Pipeline of Autoimmune Disease Therapeutics2022-11-09T22:59:01-08:00

NMPA Approves Suzhou Omni’s Compound Ipratropium Bromide Solution for Inhalation to Treat Symptoms of COPD and Asthma

NMPA Approves Suzhou Omni’s Compound Ipratropium Bromide Solution for Inhalation to Treat Symptoms of COPD and Asthma2022-09-30T02:06:18-07:00

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older2022-08-03T22:23:46-07:00

Avistone Pharmaceuticals Secures $200M Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital

Avistone Pharmaceuticals Secures $200M Strategic Investment from Vivo Capital, Bain Capital and Primavera Capital2022-03-09T22:05:12-08:00

PALO ALTO
GLOBAL HEADQUARTERS

BEIJING
 

SHANGHAI  
 

TAIPEI   
 

HONG KONG    
 

ESG | Privacy Policy | Email: info@vivocapital.com
Vivo Capital®, SEC registered, effective 6/19/2014. All rights reserved.
Go to Top